Cargando…

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma

INTRODUCTION: Sinonasal mucosal melanoma (SNMM) originates from melanocytes. Currently, the main treatment methods, including surgery, radiotherapy and chemotherapy, have little effect on the recurrence and metastasis of SNMM. However, targeted therapy may be a breakthrough in treating SNMM. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Jun, Yu, Yaner, Zhou, Yangkun, Ji, Qing, Qian, Wenkang, Jia, Dongdong, Jin, Gu, Qi, Yajun, Li, Xin, Li, Ningning, Li, Tao, Fang, Meiyu, Jin, Hongchuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632292/ https://www.ncbi.nlm.nih.gov/pubmed/36338718 http://dx.doi.org/10.3389/fonc.2022.942258

Ejemplares similares

Evolution in Sinonasal Mucosal Melanoma Management
por: Richa, Tony, et al.
Publicado: (2022)

PTEN Methylation Dependent Sinonasal Mucosal Melanoma
por: Lee, Sang Hee, et al.
Publicado: (2016)

Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma
por: Na’ara, Shorook, et al.
Publicado: (2020)

Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib
por: He, Yueming, et al.
Publicado: (2019)

High-dose proton beam therapy for sinonasal mucosal malignant melanoma
por: Fuji, Hiroshi, et al.
Publicado: (2014)

Sinonasal mucosal melanoma with smooth muscle differentiation: a potential pathological diagnostic pitfall
por: Tang, Hao, et al.
Publicado: (2022)

Synergistic Effects of Crizotinib and Temozolomide in Experimental FIG-ROS1 Fusion-Positive Glioblastoma
por: Das, Arabinda, et al.
Publicado: (2015)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Ki67 Antigen as a Predictive Factor for Prognosis of Sinonasal Mucosal Melanoma
por: Kim, Dong-Kyu, et al.
Publicado: (2008)

Primary sinonasal mucosal melanoma simulated as cystic lesions: a case report
por: Shin, Sung-Ho, et al.
Publicado: (2018)

Mutation status among patients with sinonasal mucosal melanoma and its impact on survival
por: Amit, Moran, et al.
Publicado: (2017)

Sinonasal mucosal melanoma: a 10-year experience of 36 cases in China
por: Wang, Tan, et al.
Publicado: (2020)

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas
por: Colombino, Maria, et al.
Publicado: (2019)

Sinonasal Mucosal Melanoma: A Population-based Comparison of the EUROCARE and SEER Registries
por: Temmermand, David, et al.
Publicado: (2022)

Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib: A case report
por: Yang, Tao, et al.
Publicado: (2018)

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
por: Xu, Shuguang, et al.
Publicado: (2019)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion
por: Xie, Xuehua, et al.
Publicado: (2022)

A patient with classic biphasic pulmonary blastoma harboring CD74–ROS1 fusion responds to crizotinib
por: Meng, Zhaoting, et al.
Publicado: (2017)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
por: Zebary, A, et al.
Publicado: (2013)

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma
por: Karn, Anukul, et al.
Publicado: (2021)

Sinonasal mucosal melanoma presenting as a maxillary sinus mass: A case report
por: Gautam, Kamal, et al.
Publicado: (2022)

Response to crizotinib in a patient with metastatic lung spindle cell carcinoma harboring TPM3-ROS1 fusion
por: Cai, Cun-Liang, et al.
Publicado: (2019)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Primary mucosal melanoma of the sinonasal tract: Report of 18 patients and analysis of 1077 patients in the literature
por: Khademi, Bijan, et al.
Publicado: (2015)

Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma
por: Ribeiro, Maurício Fernando Silva Almeida, et al.
Publicado: (2022)

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma
por: Lan, Shaowei, et al.
Publicado: (2020)

Recurrence in a patient with a 10-year history of sinonasal mucosal melanoma manifesting as facial swelling
por: Kalogirou, Eleni-Marina, et al.
Publicado: (2017)

Survival benefits from concomitant chemoradiotherapy before radical surgery in stage IVA sinonasal mucosal melanoma?
por: Hafström, Anna, et al.
Publicado: (2019)

A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report
por: Li, Juming, et al.
Publicado: (2020)

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion
por: Shu, Yun, et al.
Publicado: (2023)

Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report
por: Shu, Yun, et al.
Publicado: (2020)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
por: Lin, YunYu, et al.
Publicado: (2022)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants
por: Xu, Haiyan, et al.
Publicado: (2020)

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
por: Satish, Tejus, et al.
Publicado: (2021)

ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance
por: Ye, Mingxiang, et al.
Publicado: (2016)

A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report
por: Zhou, Ning, et al.
Publicado: (2018)

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging
por: Maurer, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_edovgqum1mv8h0f5enfhn0lits